Mavacamten in the Real World: Study Demonstrates Safe Reduction in Eligibility for Septal Reduction Therapy
Researchers report on successful use of mavacamten for hypertrophic cardiomyopathy under the REMS program in a real-world study. Real-world study shows a low rate of mavacamten interruption and feasibility of managing the drug under the REMS program.